These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33647441)

  • 21. Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS.
    Wu B; Luo M; Wu F; He Z; Li Y; Xu T
    Front Pharmacol; 2022; 13():692828. PubMed ID: 35401177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic.
    Grandvuillemin A; Rocher F; Valnet-Rabier MB; Drici MD; Dautriche A;
    Therapie; 2023; 78(5):523-529. PubMed ID: 36754694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System.
    Rafaniello C; Ferrajolo C; Sullo MG; Gaio M; Zinzi A; Scavone C; Gargano F; Coscioni E; Rossi F; Capuano A
    Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34202350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
    Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
    Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System.
    Alsuhaibani DS; Edrees HH; Alshammari TM
    Saudi Pharm J; 2023 Jul; 31(7):1360-1366. PubMed ID: 37304358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study.
    Alsowaida YS; Shehadeh F; Kalligeros M; Mylonakis E
    Front Pharmacol; 2023; 14():1106044. PubMed ID: 36817161
    [No Abstract]   [Full Text] [Related]  

  • 29. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
    Lee S; Yang JW; Jung SY; Kim MS; Yon DK; Lee SW; Kang HC; Dragioti E; Tizaoui K; Jacob L; Koyanagi A; Salem JE; Kostev K; Lascu A; Shin JI; Kim JH; Smith L
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7390-7397. PubMed ID: 34919240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.
    Selvarajan S; Anandaradje A; Shivabasappa S; Melepurakkal Sadanandan D; Nair NS; George M
    Br J Clin Pharmacol; 2022 Sep; 88(9):4080-4091. PubMed ID: 35357033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.
    Schreiber A; Bauzon JS; Batra K; Mohammed S; Lee K; Houshmand N; Pham U; Cosme C; Inciong K; Al-Taweel O; Nasser K; Rana J; Sossou C; Go A; Hawwass D; Diep J; Ahsan CH
    Clin Drug Investig; 2022 Sep; 42(9):763-774. PubMed ID: 35978159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 34. Bradycardia and Outcomes in COVID-19 Patients on Remdesivir: A Multicenter Retrospective Study.
    Umeh CA; Maguwudze S; Kaur H; Dimowo O; Naderi N; Safdarpour A; Hussein T; Gupta R
    Cardiol Res; 2023 Jun; 14(3):192-200. PubMed ID: 37304919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
    Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
    JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.
    Dernoncourt A; Schmidt J; Duhaut P; Liabeuf S; Gras-Champel V; Masmoudi K; Bennis Y; Batteux B
    Fundam Clin Pharmacol; 2022 Feb; 36(1):199-209. PubMed ID: 33973280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remdesivir-Induced Extreme Sinus Bradycardia in COVID-19.
    Wasef N; Hamilton S; Fatima T; Osgood E
    Cureus; 2022 Jul; 14(7):e27307. PubMed ID: 35910702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
    WHO Solidarity Trial Consortium
    Lancet; 2022 May; 399(10339):1941-1953. PubMed ID: 35512728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmarketing Reporting of Paxlovid-Related Dysgeusia: A Real-World Pharmacovigilance Study.
    Cvancara DJ; Baertsch HC; Lehmann AE; Humphreys IM; Farrell NF; Marshall TB; Bhatt NK; Abuzeid WM; Jafari A
    Otolaryngol Head Neck Surg; 2023 Jul; 169(1):55-61. PubMed ID: 36821807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Remdesivir use with bradycardia: A systematic review and meta-analysis.
    Ishisaka Y; Aikawa T; Malik A; Kampaktsis PN; Briasoulis A; Kuno T
    J Med Virol; 2023 Aug; 95(8):e29018. PubMed ID: 37539782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.